- Author January 2023
- Category eNews
- DATE 25 Jan 2023
Australia New Zealand Gynaecological Oncology Group
ANZGOG 2023 Annual Scientific Meeting
ANZGOG’s 2023 Annual Scientific Meeting will be held 22-24 March 2023 at the Hilton Hotel, Brisbane Queensland. “Improving the lived experience of patients with gynaecological cancers” is the theme for the meeting.
We will review the key advances over the last 5-10 years in gynaecological cancers that have defined new standards of care, improved survival and quality of life. Major challenges remain in optimising patient care and meeting the needs of all patients, including culturally diverse and marginalised populations. We can and will rise to the challenge.
We are pleased to announce our distinguished international speakers: Prof Iain McNeish, Prof Rene Pareja and Dr Ina Jürgenliemk-Schulz.
ANZGOG’s Annual Scientific Meeting brings together national and international experts in gynaecological medicine, radiation and surgical oncology, pathology, basic scientists, translational and quality of life researchers, study coordinators and nurses, as well as our partners in the pharmaceutical industry.
The meeting enables attendees to learn about the latest developments in gynaecological cancer and provides education and capacity-building opportunities amongst members and industry personnel. The Pure Science Symposium is the forum for scientists to learn about the cutting-edge research and developments in the pre-clinical and translational space.
Earlybird closes on Wednesday, 1 February 2023, so register now to secure your space. For more information, please visit www.anzgogasm.org.au
We look forward to seeing you in Brisbane for a rich and stimulating conference.
Powering research development
ANZGOG continues to expand its trials in operation, in development and in the pipeline. We are fortunate to have 1200 dedicated members working locally and globally to improve life for women affected by gynaecological cancer through research.
We were delighted to be able to open three studies to recruitment this year – HyNOVA, ADELE and PARAGON-II. On the other end of the trial cycle, seven studies closed to recruitment after meeting significant recruitment milestones:
- The international AtTEnd trial, led by ANZGOG in ANZ, reached its recruitment target of 550 participants, including 48 participants from ANZ.
- TIPS, an ovarian cancer surgical feasibility study, reached 100% recruitment after successfully recruiting its target of 47 patients.
- ICON9, an international phase III randomised study, recruited a total of 111 patients (ANZ target was 110).
- SOLACE2, an ovarian cancer study part of the OASIS Initiative, also reached 100% recruitment, recruiting 114 women across Australia.
We thank all participating women and their families, participating hospitals and collaborating trial teams for their long-term commitment to the studies.
ANZGOG trial update
ANZGOG clinical trials open to recruitment:
- 2 ovarian cancer trials: ECHO and HyNOVA in collaboration with the NHRMC Clinical trials Centre, at the University of Sydney
- 2 endometrial cancer trials: ENDO-3 in collaboration with Queensland Centre for Gynaecological Cancer and ADELE in collaboration with the NHRMC Clinical trials Centre, at the University of Sydney
- 1 ovarian and endometrial cancer trial: PARAGON II in collaboration with NHMRC Clinical Trials Centre, at the University of Sydney
ANZGOG clinical trials in start-up:
- 1 ovarian and endometrial cancer trial: EPOCH
- 1 cervical cancer trial: ITTACc
- 1 Quality of Live/End of life study: PEACE
For more information on ANZGOG’s trials, please visit our website.

Join Australia's leading oncology community & make an impact
Become a COSA memberTwitter
@COSAoncology
Follow

COSAoncology 8 hours ago
This Sunday 24 September is #WorldCancerResearchDay when we reflect on the importance of supporting and promoting research on the causes, prevention and early detection of cancer as a key element in controlling the disease. https://t.co/qxVjnR9ibm
Read More >
COSAoncology yesterday
RT by @COSAoncology: @rayychan @FlindersCFI @CEIH_SA @COSAoncology @survonc @NNRTnews @Flinders @FlindersHMRI Terrific discussions and energ…
Read More >
COSAoncology yesterday
RT by @COSAoncology: The 2023 COSA ASM is approaching! Such a wonderful opportunity to come together. I’m really looking forward to presentin…
Read More >
COSAoncology yesterday
RT by @COSAoncology: Finally locked in the @COSAoncology ASM. Better late than never 🤓 Looking forward to the festivities, science and networki…
Read More >
COSAoncology yesterday
RT by @COSAoncology: And how good is it that regional sites are included at the start of the program? @RtnVic @awrccentre @VCCCAlliance @COS…
Read More >
COSAoncology yesterday
There are three dinner symposia on the first night of the #COSA23 ASM, but spaces are limited, so make a selection here https://t.co/ZzF6XclB4D and update your ASM registration details soon if you don't want to miss out! https://t.co/rHobOzn1HP
Read More >
COSAoncology 2 days ago
Today's National Press Club Address was @MelanomaAus's @ProfRScolyerMIA and @ProfGLongMIA on the topic 'Melanoma science in the race against brain cancer.' https://t.co/gAXxeWHp6n
Read More >
COSAoncology 2 days ago
RT by @COSAoncology: Delighted to lead this team in #Scanxiety #cancercare providing voice to people in #evidence sysnthesis with clear impl…
Read More >
COSAoncology 3 days ago
RT by @COSAoncology: A shoutout to all the amazing #cancer dietitians I’m blessed to know, work with and be inspired by this #DietitiansDay20…
Read More >
COSAoncology 3 days ago
New 2 minute Quickfire video: Prof David Ball AO, radiation oncologist and 2012 recipient of COSA's Tom Reeve Award, discusses MDTs, SABR and why he values his COSA membership. #COSA23 https://t.co/8KUmODtoJq
Read More >